Literature DB >> 15570403

Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.

Basem M Abdallah1, Lis S Stilgren, Nis Nissen, Moustapha Kassem, Hans R I Jørgensen, Bo Abrahamsen.   

Abstract

RANKL (receptor activator of NF-kappaB) is a potent physiological inducer of osteoclastogenesis. Its actions are blocked by the decoy receptor osteoprotegerin (OPG), and treatment with OPG blocks bone resorption in postmenopausal women. Both positive and negative associations between serum OPG and bone mineral density (BMD) have been reported in the literature. We hypothesized that decreased OPG production relative to RANKL within bone itself could lead to increased risk of osteoporotic fracture. We included ten women with hip fracture (age 76.3 +/- 8.0 years, N.S, : hip BMD 0.686 +/- 1.3 g/cm2, P < 0.05) and 24 women with osteoarthrosis of the hip (age 72.8 +/- 7.2 years, hip BMD 0.832 +/- 1.1 g/cm(2)). Transiliac biopsies were obtained at the time of surgery. Total RNA was extracted from biopsies and reverse-transcribed. Real-time quantification of mRNA was performed with a SYBR Green I real time PCR assay, calculating relative gene expression with normalization of results for beta actin mRNA. Actin normalized mRNA levels for OPG and interleukin (IL)-6 were significantly lower in fracture patients, with a significantly higher RANKL/OPG ratio in patients with fractures. There was no significant difference in tumor necrosis factor (TNF), IL-1, IL-1ra, or IL-7 expression. IL-6 mRNA levels were lower in fracture patients (P < 0.05). The effect of increased RANKL/OPG ratio (Z = 2.08, P < 0.05) on fracture risk was additive to that of hip BMD T score (Z = -1.95, P < 0.05) when assessed using logistic regression. Elderly women with hip fractures exhibit an increased RANKL/OPG mRNA content of iliac bone. This is associated with increased fracture susceptibility, which is not in itself explained by low BMD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570403     DOI: 10.1007/s00223-004-0074-4

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  19 in total

1.  Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Authors:  Yang Yang; Yongsheng Ren; Vishnu C Ramani; Li Nan; Larry J Suva; Ralph D Sanderson
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

Authors:  H Dobnig; L C Hofbauer; V Viereck; B Obermayer-Pietsch; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2006-01-25       Impact factor: 4.507

3.  Can Hip Fracture Prediction in Women be Estimated beyond Bone Mineral Density Measurement Alone?

Authors:  Piet Geusens; Tineke van Geel; Joop van den Bergh
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-04       Impact factor: 5.346

4.  Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.

Authors:  Vishnu C Ramani; Yang Yang; Yongsheng Ren; Li Nan; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2010-12-03       Impact factor: 5.157

Review 5.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

6.  Triglyceride metabolism in bone tissue is associated with osteoblast and osteoclast differentiation: a gene expression study.

Authors:  Jana Dragojevič; Janja Zupan; Gregor Haring; Simon Herman; Radko Komadina; Janja Marc
Journal:  J Bone Miner Metab       Date:  2013-04-16       Impact factor: 2.626

7.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

8.  Effect of age on regulation of human osteoclast differentiation.

Authors:  Ping-Lin Chung; Shuanhu Zhou; Behnam Eslami; Longxiang Shen; Meryl S LeBoff; Julie Glowacki
Journal:  J Cell Biochem       Date:  2014-08       Impact factor: 4.429

Review 9.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

10.  Expression of bone resorption genes in osteoarthritis and in osteoporosis.

Authors:  Darja Bitenc Logar; Radko Komadina; Janez Prezelj; Barbara Ostanek; Zoran Trost; Janja Marc
Journal:  J Bone Miner Metab       Date:  2007-06-25       Impact factor: 2.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.